Ligand Pharmaceuticals (LGND) said Tuesday it expects 2025 core adjusted earnings of $6.00 to $6.25 per diluted share.
Analysts polled by FactSet expect $6.03.
The company said revenue for the year is expected to be between $180 million and $200 million.
Analysts surveyed by FactSet expect $183.1 million.
For 2024, the company said it continues to expect core adjusted earnings of between $5.50 and $5.70 on revenue of $160 million to $165 million. Analysts polled by FactSet expect core adjusted earnings of $5.65 on revenue of $163.4 million.
Price: 115.08, Change: -1.27, Percent Change: -1.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments